Novo Nordisk (NYSE: $NVO) shares dropped ~10% pre-market. 📉📉📉 On Friday, the drugmaker revealed that its experimental drug failed to reduce cardiovascular risk in a late-stage Phase 3 clinical trial. 🚨The sell-off occurred precisely at a key resistance level on the chart, as price attempted to break out above the 16-month-long descending trendline. So far the decline has been contained by the immediate key support zone. If this zone fails to hold, the $41 area becomes the next logical support for the bulls. The trigger level for a potential impulsive move to the upside remains a decisive daily close above $52. I remain bullish on $NVO. 📈 What's your take? Is this merely a retest, or the start of a deeper correction?👇 @steady_profits @MimoCrypto17 @TheLongInvest